Abbvie Inc
NYSE: ABBV
$177.07
+$0.12 (+0.1%)
Closing Price on November 25, 2024
ABBV Articles
24/7 Wall St. has put together a preview of AT&T, AbbVie, Starbucks and some of the major companies scheduled to share their quarterly results in the coming days.
Published:
Last Updated:
The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Published:
Last Updated:
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
Published:
Last Updated:
A top new addition to the Franchise list portfolio and three additional dividend stocks that the Jefferies team views as their top high conviction picks.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest decreased in these selected pharmaceutical stocks.
Published:
Last Updated:
With money expected to come out of the bond market, these four stocks are an attractive alternative that have solid upside potential, and they are the highest conviction picks at Jefferies.
Published:
Last Updated:
The November 15 short interest data have been compared with the previous figures, and short interest was mixed in the selected pharmaceutical stocks.
Published:
Last Updated:
With earnings for the third quarter over, and the fourth quarter of 2016 in full swing, many of the top companies we follow on Wall Street are making some changes to the lists of their high...
Published:
Last Updated:
Drug prices have been under pressure due to the campaign rhetoric, and short interest has increased in most of these selected pharmaceutical stocks.
Published:
Last Updated:
In a recent research note, the analysts at Jefferies make a big move by removing a top medical devices company from the firm's well-respected Franchise Picks list of stocks.
Published:
Last Updated:
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
Published:
Last Updated:
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Published:
Last Updated:
Four companies in four very different sectors that all offer liquidity, a degree of safety and solid dividends that should continue to rise.
Published:
Last Updated:
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated: